

## **TSCA Section 5(a)(3) Determination for Premanufacture Notice (PMN) P-19-0025**

**Number: P-19-0025**

**TSCA Section 5(a)(3) Determination:** The chemical substance is not likely to present an unreasonable risk (5(a)(3)(C))

**Chemical Name:**

Specific: 11-Docosene, CASRN 62978-77-2

**Conditions of Use (intended, known, or reasonably foreseen)<sup>1</sup>:**

Intended conditions of use (generic): Manufacture for use, and use as a hydrophobe formulation, consistent with the manufacturing, processing, use, distribution, and disposal information described in the PMN.

Known conditions of use: Applying such factors as described in footnote 1, EPA evaluated whether there are known conditions of use and found none.

Reasonably foreseen conditions of use: Applying such factors as described in footnote 1, EPA evaluated whether there are reasonably foreseen conditions of use and found, based on patents searches and a previous TSCA submission, that it is reasonably foreseen that the new chemical substance may be used as a reactant or intermediate in a number of different syntheses.

**Summary:** The chemical substance is not likely to present an unreasonable risk of injury to health or the environment, without consideration of costs or other nonrisk factors, including an unreasonable risk to a potentially exposed or susceptible subpopulation identified as relevant by the Administrator under the conditions of use, based on the risk assessment presented below. Although EPA estimated that the new chemical substance could be persistent, the new chemical substance has low potential for bioaccumulation, such that repeated exposures are not expected to be cumulative. Based on test data on analogous chemical substances and EPI (Estimation Programs Interface) Suite<sup>TM</sup>, EPA estimates that the chemical substance has low environmental

---

<sup>1</sup> Under TSCA § 3(4), the term “conditions of use” means “the circumstances, as determined by the Administrator, under which a chemical substance is intended, known, or reasonably foreseen to be manufactured, processed, distributed in commerce, used, or disposed of.” In general, EPA considers the intended conditions of use of a new chemical substance to be those identified in the section 5(a) notification. Known conditions of use include activities within the United States that result from manufacture that is exempt from PMN submission requirements. Reasonably foreseen conditions of use are future circumstances, distinct from known or intended conditions of use, under which the Administrator expects the chemical substance to be manufactured, processed, distributed, used, or disposed of. The identification of “reasonably foreseen” conditions of use will necessarily be a case-by-case determination and will be highly fact-specific. Reasonably foreseen conditions of use will not be based on hypotheticals or conjecture. EPA’s identification of conditions of use includes the expectation of compliance with federal and state laws, such as worker protection standards or disposal restrictions, unless case-specific facts indicate otherwise. Accordingly, EPA will apply its professional judgment, experience, and discretion when considering such factors as evidence of current use of the new chemical substance outside the United States, evidence that the PMN substance is sufficiently likely to be used for the same purposes as existing chemical substances that are structurally analogous to the new chemical substance, and conditions of use identified in an initial PMN submission that the submitter omits in a revised PMN. The sources EPA uses to identify reasonably foreseen conditions of use include searches of internal confidential EPA PMN databases (containing use information on analogue chemicals), other U.S. government public sources, the National Library of Medicine’s Hazardous Substances Data Bank (HSDB), the Chemical Abstract Service STN Platform, REACH Dossiers, technical encyclopedias (e.g., Kirk-Othmer and Ullmann), and Internet searches.

## TSCA Section 5(a)(3) Determination for Premanufacture Notice (PMN) P-19-0025

hazard and potential for the following human health hazards: liver and systemic toxicity, and hydrocarbon pneumonia. EPA concludes that the new chemical substance is not likely to present an unreasonable risk under the conditions of use.

**Fate:** Environmental fate is the determination of which environmental compartment(s) a chemical moves to, the expected residence time in the environmental compartment(s) and removal and degradation processes. Environmental fate is an important factor in determining exposure and thus in determining whether a chemical may present an unreasonable risk. EPA estimated physical/chemical and fate properties of this new chemical substance using data for an analogue, docosane. The new chemical substance is expected to be removed with an efficiency of 90 - 95% during wastewater treatment due to sorption and biodegradation. Removal by biodegradation is estimated to be high. Sorption to sludge is estimated to be strong, and sorption to soil and sediment is estimated to be very strong, resulting in negligible migration to groundwater. Strong sorption to organic material mitigates volatilization, thus this substance is expected to undergo negligible volatilization to air. Overall, these estimates are indicative of low potential for this chemical substance to volatilize into the air and a low potential for this chemical to migrate into groundwater.

**Persistence<sup>2</sup>:** Persistence is relevant to whether a new chemical substance is likely to present an unreasonable risk because chemicals that are not degraded in the environment at rates that prevent substantial buildup in the environment, and thus increase potential for exposure, may present a risk if the substance presents a hazard to human health or the environment. EPA estimated biodegradation half-lives of this new chemical substance using data for an analogue, docosane. EPA estimates that the aerobic biodegradation half-life of the new chemical substance is less than two months and anaerobic biodegradation half-life is two to six months. These biodegradation half-lives indicate that the new chemical substance may have limited persistence in aerobic environments (e.g., surface water) and may be persistent in anaerobic environments (e.g., sediment).

**Bioaccumulation<sup>3</sup>:** Bioaccumulation is relevant to whether a new chemical substance is likely to present an unreasonable risk because substances that bioaccumulate in aquatic and/or terrestrial species pose the potential for elevated exposures to humans and other organisms via food chains. EPA estimated the potential for this new chemical substance to bioaccumulate using EPI (Estimation Programs Interface) Suite<sup>TM</sup>, a suite of physical/chemical property and environmental fate estimation programs (<http://www.epa.gov/tsca-screening-tools/epi-suite.htm>)

---

<sup>2</sup> Persistence: A chemical substance is considered to have limited persistence if it has a half-life in water, soil or sediment of less than 2 months or there are equivalent or analogous data. A chemical substance is considered to be persistent if it has a half-life in water, soil or sediments of greater than 2 months but less than or equal to 6 months or if there are equivalent or analogous data. A chemical substance is considered to be very persistent if it has a half-life in water, soil or sediments of greater than 6 months or there are equivalent or analogous data. (64 FR 60194; November 4, 1999)

<sup>3</sup> Bioaccumulation: A chemical substance is considered to have a low potential for bioaccumulation if there are bioconcentration factors (BCF) or bioaccumulation factors (BAF) of less than 1,000 or there are equivalent or analogous data. A chemical substance is considered to be bioaccumulative if there are BCFs or BAFs of 1,000 or greater and less than or equal to 5,000 or there are equivalent or analogous data. A chemical substance is considered to be very bioaccumulative if there are BCFs or BAFs of 5,000 or greater or there are equivalent or analogous data. (64 FR 60194; November 4 1999)

## TSCA Section 5(a)(3) Determination for Premanufacture Notice (PMN) P-19-0025

[estimation-program-interface](#)) and data for analogous alkanes (*i.e.*, hexadecane). EPA estimates the new chemical substance has low bioaccumulation potential using EPI Suite<sup>TM</sup> (bioconcentration factor = 40) and measured data for hexadecane indicating a BCF of 9 to 48. Although EPA estimates that this new chemical substance could be persistent in anaerobic environments, the substance has a low potential for bioaccumulation, such that repeated exposures are not expected to cause food-chain effects via accumulation in exposed organisms.

**Human Health Hazard<sup>4</sup>:** Human health hazard is relevant to whether a new chemical substance is likely to present an unreasonable risk because the significance of the risk is dependent upon both the hazard (or toxicity) of the chemical substance and the extent of exposure to the substance. EPA estimated the human health hazard of this chemical substance based on its estimated physical/chemical properties, by comparing it to structurally analogous chemical substances for which there are data on human health hazard, and other structural information. Absorption of the new chemical substance is expected to be poor to nil via all routes based on physical/chemical properties. EPA identified hydrocarbon pneumonia hazard if inhaled based on data on analogous chemicals. EPA identified liver and systemic toxicity based on data from C20-24 internal olefins. EPA identified a NOAEL of 100 mg/kg/day for liver and systemic toxicity available in an OECD SIDS Initial Assessment Profile<sup>5</sup>, which was used to derive exposure route- and population-specific points of departure for quantitative risk assessment, described below.

**Environmental Hazard<sup>6</sup>:** Environmental hazard is relevant to whether a new chemical substance is likely to present unreasonable risk because the significance of the risk is dependent

---

<sup>4</sup> A chemical substance is considered to have low human health hazard if effects are observed in animal studies with a No Observed Adverse Effect Level (NOAEL) equal to or greater than 1,000 mg/kg/day or if there are equivalent data on analogous chemical substances; a chemical substance is considered to have moderate human health hazard if effects are observed in animal studies with a NOAEL less than 1,000 mg/kg/day or if there are equivalent data on analogous chemical substances; a chemical substance is considered to have high human health hazard if there is evidence of adverse effects in humans or conclusive evidence of severe effects in animal studies with a NOAEL of less than or equal to 10 mg/kg/day or if there are equivalent data on analogous chemical substances. EPA may also use Benchmark Dose Levels (BMDL) derived from benchmark dose (BMD) modeling as points of departure for toxic effects. See <https://www.epa.gov/bmds/what-benchmark-dose-software-bmds>. Using this approach, a BMDL is associated with a benchmark response, for example a 5 or 10 % incidence of effect. The aforementioned characterizations of hazard (low, medium, high) would also apply to BMDLs. In the absence of animal data on a chemical or analogous chemical substance, EPA may use other data or information such as from in vitro assays, chemical categories (e.g., Organization for Economic Co-operation and Development, 2014 Guidance on Grouping of Chemicals, Second Edition. ENV/JM/MONO(2014)4. Series on Testing & Assessment No. 194. Environment Directorate, Organization for Economic Co-operation and Development, Paris, France. ([http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=env/jm/mono\(2014\)4&doclanguage=en](http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=env/jm/mono(2014)4&doclanguage=en))), structure-activity relationships, and/or structural alerts to support characterizing human health hazards.

<sup>5</sup> OECD SIDS document for Higher Olefins, SIAM 19, 2004.

(<https://hpvchemicals.oecd.org/ui/handler.axd?id=3908a184-d3f9-4191-a3f3-acdb4f5edeb6>).

<sup>6</sup> A chemical substance is considered to have low ecotoxicity hazard if the Fish, Daphnid and Algae LC50 values are greater than 100 mg/L, or if the Fish and Daphnid chronic values (ChVs) are greater than 10.0 mg/L, or there are not effects at saturation (occurs when water solubility of a chemical substance is lower than an effect concentration), or the log Kow value exceeds QSAR cut-offs. A chemical substance is considered to have moderate ecotoxicity hazard if the lowest of the Fish, Daphnid or Algae LC50s is greater than 1 mg/L and less than 100 mg/L, or where the Fish or Daphnid ChVs are greater than 0.1 mg/L and less than 10.0 mg/L. A chemical substance is considered to have high ecotoxicity hazard, or if either the Fish, Daphnid or Algae LC50s are less than 1 mg/L, or any Fish or Daphnid

## TSCA Section 5(a)(3) Determination for Premanufacture Notice (PMN) P-19-0025

upon both the hazard (or toxicity) of the chemical substance and the extent of exposure to the substance. EPA estimated environmental hazard of this new chemical substance using the Ecological Structure Activity Relationships (ECOSAR) Predictive Model (<https://www.epa.gov/tsc-screening-tools/ecological-structure-activity-relationships-ecosar-predictive-model>); specifically the QSAR for neutral organics. Acute toxicity values estimated for fish, aquatic invertebrates, and algae are all no effects at saturation. Chronic toxicity values estimated for fish, aquatic invertebrates, and algae are all no effects at saturation. These toxicity values indicate that the new chemical substance is expected to have low environmental hazard. Because hazards are not expected up to the water solubility limit, acute and chronic concentrations of concern are not identified.

**Exposure:** The exposure to a new chemical substance is potentially relevant to whether a new chemical substance is likely to present unreasonable risks because the significance of the risk is dependent upon both the hazard (or toxicity) of the chemical substance and the extent of exposure to the substance.

EPA estimates occupational exposure and environmental release of the new chemical substance under the intended conditions of use described in the PMN using ChemSTEER (Chemical Screening Tool for Exposures and Environmental Releases <https://www.epa.gov/tsc-screening-tools/chemsteer-chemical-screening-tool-exposures-and-environmental-releases>). EPA uses EFAST (the Exposure and Fate Assessment Screening Tool; <https://www.epa.gov/tsc-screening-tools/e-fast-exposure-and-fate-assessment-screening-tool-version-2014>) to estimate general population, consumer, and environmental exposures.

EPA considers workers to be a potentially exposed or susceptible subpopulation (PESS) on the basis of greater exposure potential compared to the general population. EPA also considers PESS in conducting general population drinking water exposures by evaluating risks associated with water intake rates for multiple age groups, ranging from infants to adults. EPA considers consumers of specific products to be a potentially exposed or susceptible subpopulation on the basis of greater exposure potential compared to the general population who do not use specific products.

For this new chemical assessment, EPA assessed exposure to workers via the dermal route. Inhalation exposure to workers is not expected under the intended conditions of use. Inhalation exposure to workers is also not expected under the reasonably foreseen conditions of use, based on the similarity of the reasonably foreseen uses to the intended use and the low vapor pressure of the new chemical substance. Releases to water and air were estimated. Exposure to the general population was assessed via drinking water and fish ingestion. Exposure to the general population via inhalation was not assessed because releases to air are expected to be negligible (below modeling thresholds). Exposures to consumers were not assessed because consumer uses were not identified as conditions of use.

---

ChVs is less than 0.1 mg/L (Sustainable Futures <https://www.epa.gov/sustainable-futures/sustainable-futures-p2-framework-manual>).

## TSCA Section 5(a)(3) Determination for Premanufacture Notice (PMN) P-19-0025

**Risk Characterization:** EPA applies a margin of exposure approach to calculate potential human health risks of new chemicals. A benchmark (acceptable) margin of exposure is derived by applying uncertainty factors for the following types of extrapolations: intra-species extrapolation ( $UF_H = 10$  to account for variation in sensitivity among the human population), inter-species extrapolation ( $UF_A = 10$  to account for extrapolating from experimental animals to humans) and LOAEL-to-NOAEL extrapolation ( $UF_L = 10$  to account for using a LOAEL when a NOAEL is not available). Hence, in the New Chemicals Program, a benchmark MOE is typically 100 and 1000 when NOAELs and LOAELs, respectively, are used to identify hazard. When allometric scaling or pharmacokinetic modeling is used to derive an effect level, the  $UF_H$  may be reduced to 3, for a benchmark MOE of 30. The benchmark MOE is used to compare to the MOE calculated by comparing the toxicity NOAEL or LOAEL to the estimated exposure concentrations. When the calculated MOE is equal to or exceeds the benchmark MOE, the new chemical substance is not likely to present an unreasonable risk. EPA assesses risks to workers considering engineering controls described in the PMN but in the absence of personal protective equipment (PPE) such as gloves and respirators. If risks are preliminarily identified, EPA then considers whether the risks would be mitigated by the use of PPE (e.g., impervious gloves, respirator).

Risks to human health for the new chemical substance were evaluated using the route-specific effect level (i.e., NOAEL) described above. Risks were identified for workers for liver and systemic toxicity from dermal exposure (MOE = 24; benchmark MOE = 100). Risks will be mitigated if exposures are controlled by the use of appropriate PPE, including impervious gloves. EPA expects that workers will use appropriate personal protective equipment (i.e., impervious gloves), consistent with the Safety Data Sheet provided by the PMN submitter, in a manner adequate to protect them.

Risks were not identified for the general population for liver or systemic toxicity via ingestion of drinking water (MOE<sub>Adult</sub> = 4,380; MOE<sub>Infant</sub> = 1,040; benchmark MOE = 100) or fish ingestion (MOE = 2,550; benchmark MOE = 100). Risks to consumers were not evaluated because consumer uses were not identified as conditions of use.

Risks to the environment from acute and chronic exposure are not expected at any concentration of the new chemical substance soluble in water (i.e., no effects at saturation).

EPA has identified, based on patents and a previous TSCA submission, that it is reasonably foreseen that the new chemical substance may be used as a reactant or intermediate in a number of different syntheses. Because these reasonably foreseen uses are similar to the intended use described in the PMN, EPA expects that exposures and risks would be similar to those assessed for this PMN. Based on the similarity of the reasonably foreseen uses to the intended use and the low vapor pressure of the new chemical substance, EPA does not expect inhalation exposure to workers or the general population for the reasonably foreseen uses. Therefore, EPA concludes that the reasonably foreseen conditions of use are not likely to present unreasonable risk.

Because worker exposures can be controlled by PPE, no unreasonable risks to the general population or environment were identified, and there are no expected consumer exposures, EPA has determined that the new chemical substance is not likely to present unreasonable risk to human health or the environment under the conditions of use.

**TSCA Section 5(a)(3) Determination for Premanufacture Notice (PMN) P-19-0025**

03/08/2019  
Date:

/s/  
Jeffery T. Morris, Director  
Office of Pollution Prevention and Toxics